Deserted by Takeda, Mersana abandons lead drug
Mersana Therapeutics’ rocky road in developing its lead drug has culminated in the abandonment of the experimental cancer treatment, days after its high-profile partner Takeda decided to walk away from their deal.
Back in 2016, Takeda and its unit Millennium expanded a prior partnership with Mersana by securing the the ex-US commercial rights to the Cambridge, Massachusetts-based company’s then-lead preclinical antibody drug conjugate — XMT-1522 — for $60 million upfront and a host of other milestone payments, which in tandem with their existing agreement added up to a $1 billion-plus deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.